Metadata record for the manuscript: The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer

Summary

This
metadata record provides details of the data supporting the claims of the
related manuscript: “The CINSARC signature predicts the
clinical outcome in patients with Luminal B breast cancer”.

The
related study tested the prognostic value for disease-free survival (DFS) of
CINSARC, a multigene expression signature originally developed in sarcomas and shown
to have prognostic impact in various cancers, in a series of 6035 early-stage
invasive primary breast cancers.

Type of data:
prognostic value for DFS of CINSARC

Subject of
data: Homo sapiens

Sample size:
6035

Population
characteristics: All cases were invasive breast carcinomas profiled using DNA
microarrays or RNA-sequencing with expression and clinicopathological data
available. All samples are pre-treatment samples (operative specimen or diagnostic
biopsy before neo-adjuvant chemotherapy). The

detailed
characteristics of patients and tumours analysed in the present study are
available in Supplementary Table 10.

Recruitment:
publicly available transcriptomic data of invasive primary breast cancer
enrolled in 36 retrospective studies published over a 10-year period between
2002 and 2012.

Data
access

All data
sets of primary breast cancer were downloaded from the Gene Expression Omnibus
(GEO, https://www.ncbi.nlm.nih.gov/geo/), ArrayExpress (https://www.ebi.ac.uk/arrayexpress/), Genomic Data Commons (GDC, https://portal.gdc.cancer.gov/) and cBioPortal (https://www.cbioportal.org/) databases. All accession IDs are provided in Supplementary Table 10
(Table S10 revised.xlsx), which is included with this data record.

The data
underlying the figures and tables of the related article are contained in the
files ‘Goncalves_supporting_data.xlsx’ and ‘Table S8.xlsx’, which are included
with this data record.

A detailed
list of the data underlying each figure and table of the related article is
available in the file ‘Goncalves_2021_underlying_data_list.xlsx’, which is
included with this data record.

Corresponding author(s) for this study

Pr
François BERTUCCI, MD PhD, Département d’Oncologie Médicale, Institut
Paoli-Calmettes, 232 Bd. Ste-Marguerite, 13009 Marseille, France e-mail:[e-mail]
; Phone : [phone] ; Fax : [phone]

Study approval

The
details of Institutional Review Board and Ethical Committee approval and
patients’ consent for the 36 studies analysed in the related study are present
in their corresponding publications, which are listed in Supplementary Table 10
of the related article.